Nav: Home

Major trial shows breast cancer drug can hit prostate cancer Achilles heel

April 28, 2020

A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

Olaparib, a pill lacking the side effects of chemotherapy, can target an Achilles heel in prostate cancers with a weakness in their ability to repair damaged DNA. It is now on the verge of becoming approved as the first genetically targeted treatment for prostate cancer.

This precision medicine drug, a type of treatment called a PARP inhibitor which specifically targets cancer cells with faulty DNA repair genes, blocked prostate cancer growth more effectively than the modern targeted hormone treatments abiraterone and enzalutamide.

The final results from the PROfound trial, published in the prestigious journal the New England Journal of Medicine today (Tuesday), are set to herald the landmark approval of olaparib in prostate cancer in the US and Europe this year. The study was funded by AstraZeneca.

A team from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, alongside colleagues from all around the world including Northwestern University in Chicago, US, studied 387 men with advanced prostate cancer who had alterations in one or more of 15 DNA repair genes. The researchers found that using olaparib in this group of men with faulty DNA repair genes significantly delayed disease progression.

Men with prostate cancers that had faulty BRCA1, BRCA2 or ATM genes benefited the most from receiving olaparib - with their disease taking 7.4 months before it progressed, compared with 3.6 months for those who received enzalutamide and abiraterone.

Men with an alteration in any of the other 12 pre-selected DNA repair genes also benefitted from receiving olaparib.

Overall, for men with any of the 15 faulty DNA repair genes who were given olaparib, the length of time before their cancer got worse was 5.8 months on average, compared with 3.5 months with targeted hormonal treatment.

The discovery of abiraterone by The Institute of Cancer Research (ICR), and its development by the ICR and The Royal Marsden, has transformed treatment for men with advanced prostate cancer.

Researchers are excited at the prospect that olaparib - which the ICR discovered how to genetically target - could be even more effective than abiraterone in selected men with DNA repair mutations.

The overall survival of men with faulty BRCA1, BRCA2 or ATM genes was 19 months on average for those who received olaparib, compared with 15 months for those who received abiraterone or enzalutamide - despite more than 80 per cent of the men who received the targeted hormone treatments switching to olaparib when their cancer progressed and spread. However, longer follow-up will be needed to show a survival improvement conclusively.

The most frequent adverse effects were anaemia and nausea, which have been associated with olaparib in the past. But overall olaparib is a well-tolerated treatment, and much kinder on patients than chemotherapy.

PROfound is the first trial to show how crucial it is to carry out genomic testing in prostate cancer patients. It is vital to identify different patient groups based on their genetics and to tailor treatment accordingly.

Researchers are now hoping to see olaparib become available on the NHS for patients with advanced prostate cancer and faulty DNA repair genes within the next two years.

Next, they will look at combining olaparib with other treatments, with the aim of improving outcomes even further.

Study co-leader Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:

"Our findings show that olaparib - a drug which targets an Achilles heel in cancer cells while sparing normal, healthy cells - can outperform targeted hormone treatments in some men with advanced prostate cancer.

"It's exciting to see a drug which is already extending the lives of many women with ovarian and breast cancer now showing such clear benefits in prostate cancer too. I can't wait to see this drug start reaching men who could benefit from it on the NHS - hopefully in the next couple of years.

"Next, we will be assessing how we can combine olaparib with other treatments, which could help men with prostate cancer and faulty DNA repair genes live even longer."

Peter Isard, 59, a patient at The Royal Marsden, said:

"Initially after diagnosis I went onto hormone therapy and then chemotherapy. Six months after finishing chemotherapy, my PSA rose rapidly and I was told my chance of living for two years would be quite low. I came to The Royal Marsden for a second opinion and Prof de Bono found I had a genetic mutation that would make me suitable for an olaparib trial. I've been on the drug for almost two years now. I had a number of tumours in my lymph nodes, but now there is only one that is visible and I feel incredibly lucky not to have experienced any side-effects whatsoever."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"It is great to see that this treatment, which we learned how to genetically targeted at the ICR, can successfully hit an Achiles heel in some men with advanced prostate cancer. These landmark findings mean that olaparib is now set to become the first ever genetically targeted drug for the disease.

"The next step will be to find new ways to combine olaparib with other treatments in order to prevent or overcome drug resistance. It is this kind of research, which aims to target cancer's lethal ability to adapt and evolve, which we will be conducting in our pioneering Centre for Cancer Drug Discovery once it opens later this year."
-end-
For more information please contact Sarah Wells in the ICR press office on 020 7153 5582 or sarah.wells@icr.ac.uk. For enquiries out of hours, please call 07595 963 613.

The Institute of Cancer Research, London, is one of the world's most influential cancer research organisations.

The Institute of Cancer Research (ICR) has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes, discovering new targeted drugs and developing new high-precision forms of radiotherapy.

The ICR is a charity and relies on support from partner organisations, funders and the general public. A college of the University of London, it is the UK's top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk.

Institute of Cancer Research

Related Prostate Cancer Articles:

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.
The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.
Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.
First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
More Prostate Cancer News and Prostate Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Our Relationship With Water
We need water to live. But with rising seas and so many lacking clean water – water is in crisis and so are we. This hour, TED speakers explore ideas around restoring our relationship with water. Guests on the show include legal scholar Kelsey Leonard, artist LaToya Ruby Frazier, and community organizer Colette Pichon Battle.
Now Playing: Science for the People

#569 Facing Fear
What do you fear? I mean really fear? Well, ok, maybe right now that's tough. We're living in a new age and definition of fear. But what do we do about it? Eva Holland has faced her fears, including trauma and phobia. She lived to tell the tale and write a book: "Nerve: Adventures in the Science of Fear".
Now Playing: Radiolab

Uncounted
First things first: our very own Latif Nasser has an exciting new show on Netflix. He talks to Jad about the hidden forces of the world that connect us all. Then, with an eye on the upcoming election, we take a look back: at two pieces from More Perfect Season 3 about Constitutional amendments that determine who gets to vote. Former Radiolab producer Julia Longoria takes us to Washington, D.C. The capital is at the heart of our democracy, but it's not a state, and it wasn't until the 23rd Amendment that its people got the right to vote for president. But that still left DC without full representation in Congress; D.C. sends a "non-voting delegate" to the House. Julia profiles that delegate, Congresswoman Eleanor Holmes Norton, and her unique approach to fighting for power in a virtually powerless role. Second, Radiolab producer Sarah Qari looks at a current fight to lower the US voting age to 16 that harkens back to the fight for the 26th Amendment in the 1960s. Eighteen-year-olds at the time argued that if they were old enough to be drafted to fight in the War, they were old enough to have a voice in our democracy. But what about today, when even younger Americans are finding themselves at the center of national political debates? Does it mean we should lower the voting age even further? This episode was reported and produced by Julia Longoria and Sarah Qari. Check out Latif Nasser's new Netflix show Connected here. Support Radiolab today at Radiolab.org/donate.